Identification of biomarkers for immune-related adverse events

Published in Cancer

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Immune-related adverse events (irAEs) during anti-programmed death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody therapy, resulting from immune activation combined with disturbed immunologic homoeostasis, can affect any organ systems and in some cases can be lethal (Postow et al., 2018). Therefore, predictive biomarkers of irAEs are required to determine the benefit/risk ratio for patients receiving anti-PD-1/PD-L1 therapy. A comprehensive approach to identify biomarkers of irAE is lacking. We aimed to identify predictive biomarkers of irAEs to balance the benefit/risk ratio of immunotherapy patients.

Inspired by a recent study (Lee and Ruppin, 2019), we utilized an alternative strategy to combine the power of real-world pharmacovigilance data and omics data (Jing et al, 2020). We calculated the irAE reporting odds ratio (ROR) based on safety reports from the US FDA Adverse Event Reporting System (FAERS) across 26 different cancer types and evaluated the associations between 36 known immune related factors. Cytolytic activity, IFN γ signature, PD-1 expression, TCR diversity, macrophages M1, CD8+ T-cell abundance, and naive B cells showed positive association with irAE risks. Further analysis revealed that the combination of CD8+ T cells and TCR diversity achieved the best predictive accuracy. We further performed similar analysis to identify potential irAE predictors among mRNA/miRNA/lncRNA/protein expression, and nonsynonymous mutations across 26 cancer types. The top irAE risk associated factors were enriched in T-cell activation pathways. The bivariate model comprised of LCP1 and ADPGK achieved the maximum irAE predictive efficacy. We then collaborated with physician scientists and cancer biologists, and collected pretreatment tumor tissues of a cohort of 28 anti-PD-1/PD-L1 cancer patients. It is also really challenging to collect samples and conduct experiments through the COVID-19 pandemic, but our collaborators successfully made it. Indeed, the AUC of LCP1 +ADPGK in predicting irAEs was 0.80 in our validation cohort.

Our proof-of-concept study set up an analytic framework to explore irAE biomarkers and propose possible underpinning key factors, which might have important implications for management of patients with immunotherapy. Our analysis enables the study of promising signals of immune related toxicities in unprecedented large sample cohorts, while collecting both molecular data and irAE information of thousands of patients with immunotherapy requires the collaboration of multicenter with several years’ efforts. Future work is necessary to further study predictive performance of LCP1 and ADPGK in larger anti-PD-1/PD-L1 patient cohorts. We envision that LCP1 and ADPGK might enable a pre-risk-check of patients before receiving anti-PD-1/PD-L1 agents with further study. More importantly, our work suggests that the strategy that to combine the power of real-world data and omics data is robust and powerful, especially in the absence of a large number of patient samples.


Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Subscribe to the Topic

Cancer Biology
Life Sciences > Biological Sciences > Cancer Biology

Related Collections

With collections, you can get published faster and increase your visibility.

Applied Sciences

This collection highlights research and commentary in applied science. The range of topics is large, spanning all scientific disciplines, with the unifying factor being the goal to turn scientific knowledge into positive benefits for society.

Publishing Model: Open Access

Deadline: Ongoing

Materials and devices for separation, sensing, and protection

In this Collection, the editors of Nature Communications and Communications Materials welcome the submission of primary research articles that highlight the development and application of functional materials in the areas of separation, sensing, and protection.

Publishing Model: Open Access

Deadline: Jun 30, 2024